Despite a robust balance sheet and good liquidity, Pliant Th...

Despite a robust balance sheet and good liquidity, Pliant Therapeutics faced a 64% revenue shrink to US$3.5m last year, questioning its future profitability. After burning through US$124m cash and a US$155m loss, it might need to raise capital soon.